Bristol Myers Squibb disclosed a death from septic pneumonia in a multiple sclerosis patient during a CAR T trial, prompting a pause in certain trials of zolacabtagene autoleucel. This information precedes the presentation of data from the Phase 1 Breakfree-2 study at the upcoming ACTRIMS-ECTRIMS meeting.
The disclosure—which came ahead of a presentation of data from the Phase 1 Breakfree-2 study at the ACTRIMS-ECTRIMS meeting—follows Bristol Myers Squibb’s late summer revelation that it had paused certain trials of zolacabtagene autoleucel.
Original title: “BMS reveals death from septic pneumonia of multiple sclerosis patient in CAR T trial”